Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric Type 1 diabetic patients

Journal of Endocrinological Investigation

Volumn 36, Issue 8, 2013, Pages 574-578

  Bulum, T ^a   Kolaric B ^b,c   Duvnjak, L ^a  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

^c Zagreb Institute of Public Health   (Croatia)

Author keywords

Albuminuria; HDL3 cholesterol; Serum lipids; Total HDL cholesterol; Type 1 diabetes

Indexed keywords

ALBUMIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MALE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ALBUMINURIA; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED;

EID: 84881430363     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8850     Document Type: Article

References (34)

1. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of type 1 diabetes: the Linkoping Diabetes Complications Study. Diabetologia 2004, 47: 1266-72.
2. Raile K, Galler A, Hofer S, et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 2007, 30: 2523-8.
3. Coonrod BA, Ellis D, Becker DJ, et al. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 1993, 16: 1376-83.
4. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995, 332: 1251-5.
5. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003, 254: 45-66.
6. Scott LJ, Warram JH, Hanna LS, Laffel LM, Ryan L, Krolewski AS. A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 2001, 50: 2842-9.
7. Lahdenpera S, Groop PH, Tilly-Kiesi M, et al. LDL subclasses in IDDM patients: Relation to diabetic nephropathy. Diabetologia 1994, 37: 681-8.
8. Sibley SD, Hokanson JE, Steffes MW, et al. Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. Diabetes Care 1999, 22: 1165-70.
9. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The treating to new targets (TNT) study. Clin J Am Soc Nephrol 2007, 2: 1131-9.
10. Orchard TJ, Chang Y, Ferrell RE, Petro N, Ellis DE. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiplegenetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 2002, 62: 963-70.
11. Tolonen N, Forsblom C, Thorn L, et al. Relationship between lipid profiles and kidney function in patients with type 1 diabetes. Diabetologia 2008, 51: 12-20.
12. Chaturvedi N, Fuller JH, Taskinen MR. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications in type 1 diabetes. Diabetes Care 2001, 24: 2071-7.
13. Marcovecchio ML, Dalton RN, Prevost AT, et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care 2009, 32: 658-63.
14. Dullaart R, Dikkeschei L, Doorenbos H. Alterations in serum lipids and apolipoproteins in male type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1989, 32: 685-9.
15. Thomas MC, Rosengard-Bärlund M, Mills V, et al. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 2006, 29: 317-22.
16. Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabet Med 2000, 26: 254-64.
17. Hirano T, Naito H, Kurokawa M, et al. High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy. Atherosclerosis 1996, 123: 57-72.
18. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348: 2285-93.
19. Groop PH, Thomas MC, Rosengard-Bärlund M, et al. HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes. Diabetes Care 2007, 30: 2706-7.
20. Molitch ME, Rupp D, Carnethon M. Higher levels of HDL cholesterol are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes. Diabetes Care 2006, 29: 78-82.
21. Tolonen N, Forsblom C, Thorn J, et al. Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes. Diabetologia 2009, 52: 2522-30.
22. Bulum T, Duvnjak L, Prkacin I. Lower levels of HDL2 cholesterol are associated with microalbuminuria in patients with type 1 diabetes. Acta Med Croatica 2011, 65: 243-50.
23. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286: 421-6.
24. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150: 604-12.
25. Standards of Medical Care in Diabetes - 2012. Diabetes Care 2012, 35 (Suppl. 1): S11-63.
26. Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004, 328: 1105.
27. Epidemiology of Diabetes Interventions and Complications (EDIC)/Diabetes Control and Complications Trial (DCCT) Study Group: Sustained effects of intensive treatment of type 1 diabetes mellitus on the development and progression of diabetic nephropathy. JAMA 2003, 290: 2159-67.
28. Jenkins AJ, Lyons TJ, Zheng D, et al. Lipoproteins in the DCCT/ EDIC cohort: associations with diabetic nephropathy. Kidney Int 2003, 64: 817-28.
29. Klein R, Klein BE, Moss SE, Cruickshanks KJ, Brazy PC. The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 1999, 22: 743-51.
30. Genest J jr. Genetics and prevention: a new look at high-density lipoprotein cholesterol. Cardiol Rev 2002, 10: 61-71.
31. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001,285: 2486-96.
32. Kahri J, Groop PH, Elliott T, Viberti G, Taskinen MR. Plasma cholesteryl ester transfer protein and its relationship to plasma lipoproteins and apolipoprotein A-1-containing lipoproteins in IDDM patients with microalbuminuria and clinical nephropathy. Diabetes Care 1994, 17: 412-9.
33. Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis 1996, 121: 1-12.
34. Yu S, Yarnell JWG, Sweetnam P, Bolton CH. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow- up in the Caerphilly Study. Atherosclerosis 2003, 166: 331-8.